Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417660 · ClinicalTrials.gov registry record · Phase 2
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
A Phase 2 study of Thymic Cancer and Thymic Epithelial Tumor, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04417660 is a Phase 2 study of Thymic Cancer and Thymic Epithelial Tumor that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 9 participants, below the 21-participant average among 4 other Thymic Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04417660, a Phase 2 study of Thymic Cancer and Thymic Epithelial Tumor, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatment for these diseases. But in many cases, the disease returns after treatment. Researchers want to see if a new drug can help. Objective: To see if bintrafusp alfa (M7824) is an effective treatment for thymoma and thymic carcinoma. Eligibility: People age 18 and older who have thymoma or thymic cancer and their disease returned or progressed after treatment with at least one platinum-containing chemotherapy treatment plan. Design: Participants will be screened under a separate protocol. Their medical, medicine, and treatment history will be reviewed. They will have a tumor biopsy if they do not have a sample. Participants will get the study drug once every 2 weeks as an intravenous infusion. For this, a small plastic tube is put into an arm vein. During the study, participants will undergo the following: Medicine review Physical exam Review of their symptoms and their ability to perform their normal activities Blood and urine tests Thigh muscle scan (using MRI) Tumor assessment (using MRI or CT) Heart and lung function tests Thyroid gland test Skin assessment. Participants may have tumor biopsies. Some of their blood and biopsy samples will be used for gene testing. Participants may take the study drug until their disease worsens or they cannot tolerate treatment. Participants will have follow-up visits 2 and 6 weeks after stopping treatment. Then they will have long-term follow-up visits every 3 months. These may include imaging scans. Visits may be done by phone, with scans (if needed) done at their doctor s office.
Conditions Studied
Interventions
- DRUG M7824
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-12-26 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417660
The ClinicalTrials.gov registry entry for NCT04417660 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 21-participant average among 4 other Thymic Cancer trials with a reported enrollment target (57% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thymic Cancer appearing as the primary indexed condition, and to 1 intervention - of which M7824 is the first listed.
NCT04417660 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04417660 about?
NCT04417660 is a clinical study titled "Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma". Background: Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatment for these diseases. But in many cases, the disease returns after treatment. Researchers want to see if a new drug can help. Objective: To see if bintrafusp alfa (M7824) is an...
What is the current status of trial NCT04417660?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-12-26. Estimated completion is 2026-12-31.
What conditions does trial NCT04417660 study?
This clinical trial studies the following conditions: Thymic Cancer, Thymic Epithelial Tumor, Recurrent Thymoma.
What interventions are being tested in trial NCT04417660?
The interventions under investigation include: M7824 (DRUG).
Who is sponsoring clinical trial NCT04417660?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04417660 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thymic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PT-112 in Subjects With Thymoma and Thymic Carcinoma
RECRUITING · Phase 2
-
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
COMPLETED · Phase 2
-
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
COMPLETED · Phase 2
-
Genetic Evaluation of Families With Endocrine Cancers
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.